Incretin Atlas › Trials › VENTURE-Oral (phase 2)
VENTURE-Oral (phase 2)
VK2735 · obesity
Design
- Molecule(s)
- VK2735
- Population
- obesity
- Phase
- 2
- Participants
- 40
- Duration
- 13 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| oral VK2735 90 mg daily | obesity | 13 | 40 | — | —−11.1 % vs −1.3 % estimand not specified | — | — | 25.0 vs 18.0 | — | — | — | — | verified |
| oral VK2735 120 mg daily | obesity | 13 | 40 | — | —−12.2 % vs −1.3 % estimand not specified | — | — | 38.0 vs 18.0 | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- oral VK2735 90 mg daily: Press release: estimand not stated Nausea and vomiting are reported only as drug-related events by severity (not shown on the axis).
- oral VK2735 120 mg daily: Press release: estimand not stated Nausea and vomiting are reported only as drug-related events by severity (not shown on the axis).
Verbatim quotes from the source (4)
- oral VK2735 90 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
- oral VK2735 90 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %
- oral VK2735 120 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
- oral VK2735 120 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: VENTURE-Oral (phase 2). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture-oral/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.